FI943171A - Ureasbaserad vaccin mot Helicobacter-infektion - Google Patents

Ureasbaserad vaccin mot Helicobacter-infektion Download PDF

Info

Publication number
FI943171A
FI943171A FI943171A FI943171A FI943171A FI 943171 A FI943171 A FI 943171A FI 943171 A FI943171 A FI 943171A FI 943171 A FI943171 A FI 943171A FI 943171 A FI943171 A FI 943171A
Authority
FI
Finland
Prior art keywords
urease
vaccine against
based vaccine
helicobacter infection
against helicobacter
Prior art date
Application number
FI943171A
Other languages
English (en)
Finnish (fi)
Other versions
FI112032B (sv
FI943171A0 (sv
Inventor
Pierre Michetti
Andre Blum
Catherine Davin
Rainer Iiaas
Irene Corthesy-Theulaz
Jean-Pierre Kraehenbuhl
Emilia Saraga
Original Assignee
Oravax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25517797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI943171(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oravax Inc filed Critical Oravax Inc
Publication of FI943171A0 publication Critical patent/FI943171A0/sv
Publication of FI943171A publication Critical patent/FI943171A/sv
Application granted granted Critical
Publication of FI112032B publication Critical patent/FI112032B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI943171A 1992-11-03 1994-07-01 Förfarande för framställning av ett ureasbaserad vaccin mot Helicobacter-infektion FI112032B (sv)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US97099692A 1992-11-03 1992-11-03
US97099692 1992-11-03
US8593893 1993-07-06
US08/085,938 US5972336A (en) 1992-11-03 1993-07-06 Urease-based vaccine against helicobacter infection
EP9303059 1993-11-02
PCT/EP1993/003059 WO1994009823A1 (en) 1992-11-03 1993-11-02 Urease-based vaccine against helicobacter infection

Publications (3)

Publication Number Publication Date
FI943171A0 FI943171A0 (sv) 1994-07-01
FI943171A true FI943171A (sv) 1994-09-01
FI112032B FI112032B (sv) 2003-10-31

Family

ID=25517797

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943171A FI112032B (sv) 1992-11-03 1994-07-01 Förfarande för framställning av ett ureasbaserad vaccin mot Helicobacter-infektion

Country Status (29)

Country Link
US (1) US5972336A (sv)
EP (2) EP0625053B1 (sv)
JP (1) JPH07503255A (sv)
KR (1) KR100287424B1 (sv)
CN (1) CN1111429C (sv)
AT (1) ATE217196T1 (sv)
AU (2) AU678195C (sv)
BR (1) BR9305711A (sv)
CA (1) CA2127283A1 (sv)
CZ (1) CZ284416B6 (sv)
DE (1) DE69331901T2 (sv)
DK (1) DK0625053T3 (sv)
ES (1) ES2176232T3 (sv)
FI (1) FI112032B (sv)
GE (1) GEP20012429B (sv)
HU (1) HU219760B (sv)
IL (1) IL107474A (sv)
MX (1) MX9306841A (sv)
NO (1) NO942490L (sv)
NZ (2) NZ258118A (sv)
OA (1) OA10087A (sv)
PL (1) PL174448B1 (sv)
PT (1) PT625053E (sv)
RO (1) RO114870B1 (sv)
RU (1) RU2125891C1 (sv)
SG (1) SG70978A1 (sv)
SK (1) SK280619B6 (sv)
WO (1) WO1994009823A1 (sv)
ZA (1) ZA938203B (sv)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
WO1995014093A1 (en) 1993-05-19 1995-05-26 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
NZ269124A (en) * 1993-07-27 1997-06-24 Csl Ltd Vaccine comprising helicobacter antigens and its use in treating such infections
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
AU702878B2 (en) * 1994-06-08 1999-03-11 Csl Limited Treatment and prevention of helicobacter infection
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
DE69529219T2 (de) * 1994-07-01 2003-11-06 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Helicobacter proteine und impstoffe
DE69637947D1 (de) * 1995-04-28 2009-07-23 Merieux Oravax Snc Multimerer, rekombinanter urease impfstoff
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine
WO1997005267A2 (en) * 1995-07-26 1997-02-13 Maxim Pharmaceuticals Mucosal delivery of polynucleotides
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
US20020026035A1 (en) * 1997-04-01 2002-02-28 Harold Kleanthous Helicobacter ghpo 1360 and ghpo 750 polypeptides and corresponding polynucleotide molecules
AU7537598A (en) * 1997-04-30 1998-11-24 Pasteur Merieux Serums Et Vaccins Dna based anti-(helicobacter) vaccine composition
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US5985631A (en) 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20020151462A1 (en) * 1998-02-19 2002-10-17 Ling Lissolo Helicobacter pylori membrane proteins
GB9807721D0 (en) * 1998-04-08 1998-06-10 Chiron Spa Antigen
KR20010088302A (ko) 1998-06-19 2001-09-26 추후 제출 헬리코박터 감염에 대한 비경구 면역화 방법에 있어서의ｌｔ 및 ｃｔ
US6190667B1 (en) 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
AU8464398A (en) * 1998-07-16 2000-02-07 Cheil Jedang Corporation Urease based vaccine against (helicobacter) infection
CN1338947B (zh) * 1999-02-05 2012-11-14 爱尔开-阿贝优公司 粘膜递送系统
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
DK2116257T3 (da) 2000-08-09 2013-02-04 Alk Abello As Parenterale vaccineformuleringer og anvendelser deraf
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
AUPR524101A0 (en) * 2001-05-25 2001-06-21 Council Of The Queensland Institute Of Medical Research, The Antigen targeting
WO2002098369A2 (en) * 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
ATE451386T1 (de) * 2001-06-07 2009-12-15 Wyeth Corp Mutantenformen von cholera holotoxin als adjuvans
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN100460014C (zh) * 2006-07-20 2009-02-11 中国人民解放军第三军医大学 基于尿素酶b亚单位活性片段的幽门螺杆菌疫苗及其制备方法
AU2007317206B2 (en) * 2006-11-10 2013-04-18 Ondek Pty Ltd Methods and devices for the delivery of peptides into the gastric mucosa
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
KR100982489B1 (ko) * 2007-12-17 2010-09-15 대구한의대학교산학협력단 헬리코박터 파일로리로부터 유래된 항원을 이용하여헬리코박터 파일로리 특이 항체 생산을 위한 백신을제조하는 방법
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) * 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
PL218700B1 (pl) 2012-03-29 2015-01-30 Gdański Univ Medyczny Doustna szczepionka zawierająca przetrwalniki Bacillus subtilis oraz jej zastosowanie do immunizacji przeciwko Helicobacter pylori
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP2837939A1 (en) * 2013-08-13 2015-02-18 Technische Universität München Method for the detection of H.pylori infection
SG10201912301XA (en) 2013-11-04 2020-02-27 Uti Lp Methods and compositions for sustained immunotherapy
US12011480B2 (en) 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5268276A (en) * 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
JPH04169539A (ja) * 1990-11-01 1992-06-17 Imuno Japan:Kk 消化器疾患治療・予防剤およびその製造方法
JPH06507494A (ja) * 1991-04-26 1994-08-25 カレノフ，エマニユエル 細菌性アレルゲンにより惹起される疾患の検出及び治療方法
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US5859219A (en) * 1992-02-26 1999-01-12 Vanderbilt University Purified vacuolating toxin from Helicobacter pylori and methods to use same
EP0967279B1 (en) * 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
US5679564A (en) * 1994-10-05 1997-10-21 Antex Biologics, Inc. Methods for producing enhanced antigenic campylobacter bacteria and vaccines
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine

Also Published As

Publication number Publication date
CN1094640A (zh) 1994-11-09
PT625053E (pt) 2002-09-30
AU2003270987A1 (en) 2004-01-22
DE69331901D1 (de) 2002-06-13
AU5561994A (en) 1994-05-24
CZ284416B6 (cs) 1998-11-11
US5972336A (en) 1999-10-26
EP0625053B1 (en) 2002-05-08
JPH07503255A (ja) 1995-04-06
DE69331901T2 (de) 2002-10-31
IL107474A (en) 1998-09-24
EP1170016A2 (en) 2002-01-09
WO1994009823A1 (en) 1994-05-11
AU678195B2 (en) 1997-05-22
EP0625053A1 (en) 1994-11-23
HU219760B (hu) 2001-07-30
RU2125891C1 (ru) 1999-02-10
CN1111429C (zh) 2003-06-18
NO942490L (no) 1994-08-22
NZ299149A (en) 1997-12-19
FI112032B (sv) 2003-10-31
BR9305711A (pt) 1997-02-18
CA2127283A1 (en) 1994-05-11
ES2176232T3 (es) 2002-12-01
HU9402261D0 (en) 1994-10-28
NO942490D0 (no) 1994-07-01
PL174448B1 (pl) 1998-07-31
RO114870B1 (ro) 1999-08-30
EP1170016A3 (en) 2002-03-06
FI943171A0 (sv) 1994-07-01
CZ160994A3 (en) 1995-04-12
DK0625053T3 (da) 2002-08-12
MX9306841A (es) 1995-01-31
ZA938203B (en) 1994-06-09
SG70978A1 (en) 2000-03-21
SK79394A3 (en) 1996-09-04
ATE217196T1 (de) 2002-05-15
HUT69938A (en) 1995-09-28
PL304419A1 (en) 1995-01-09
GEP20012429B (en) 2001-05-25
NZ258118A (en) 1997-04-24
OA10087A (en) 1996-12-18
SK280619B6 (sk) 2000-05-16
AU678195C (en) 2003-06-12
IL107474A0 (en) 1994-02-27
KR100287424B1 (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
FI943171A (sv) Ureasbaserad vaccin mot Helicobacter-infektion
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
ES2092306T3 (es) Adyuvante para vacunas.
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
RU93058676A (ru) Оральное лечение геликобактерной инфекции
FI851859L (fi) Antigenpreparat och isolering av saodana preparat.
KR970009347B1 (en) Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
IL130075A0 (en) A vaccine for eliciting an immune response to an antigen in an animal
NZ314585A (en) Method of treating H. Pylori associated gastroduodenal disease
NZ192477A (en) Method for protecting dogs against virulent canine parvovirus using inactivated virus vaccine
NO991692L (no) Levende Heliobacter pylori-vaksine
GB2227936A (en) Vaccine against brucella abortus
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
FR2646776B1 (fr) Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
DK52783A (da) Vaccine indeholdende en ozon-inaktiveret mikroorganisme og fremgangsmaade til fremstilling af en saadan vaccine
ES515472A0 (es) Procedimiento para proteger anfitriones susceptibles de infeccion de hepatitis.
ATE318300T1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
ATE110964T1 (de) Pertussistoxoid-impfstoff.
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
EP0563288A4 (en) Immunopotentiation of vaccines, particularly swine pleuropneumonia vaccines
ATE62134T1 (de) Biologische zubereitungen.
NO934547L (no) Oral behandling av Helicobacter-infeksjon

Legal Events

Date Code Title Description
MA Patent expired